Gene Holdings Inc. , a clinical-stage, non-viral genetic medicines company, today announced that it has entered into an amendment to an amended and restated loan and security agreement (as amended, ...
According to DelveInsight’s latest analysis, Nipocalimab is expected to capture meaningful market share across both prevalent ...
An update from Pharmaust Limited ( (AU:NUZ)) is now available. Neurizon Therapeutics has provided a regulatory update on NUZ-001, its investigational ALS therapy, confirming that the US FDA has ...
This is the prepared text of Gov. Jared Polis’ 2026 State of the State address to the Colorado General Assembly, which he ...
Current and former Decatur residents who challenged a $52 million bond for school construction projects are declining to ...
The FDA's Fast Track designation helps to accelerate the development and review of products for serious and life-threatening conditions.
FDA Fast Track designation has been granted to CTx001 for Geographic Atrophy secondary to Age-related Macular Degeneration CTx001 is an investigational AAV-based gene therapy designed to modulate ...
Fast Track Designation Highlights Potential of Enolen to Address Unmet Medical Need for Patients with Low to Intermediate Risk, Localized Prostate Cancer Company Expects to Provide Initial Findings ...
SAN CARLOS, Calif.--(BUSINESS WIRE)--Alessa Therapeutics (“Alessa”), a clinical-stage biopharmaceutical company advancing novel localized drug delivery technology for the treatment of early-stage ...
Alessa Therapeutics ("Alessa"), a clinical-stage biopharmaceutical company advancing novel localized drug delivery technology for the treatment of early-stage prostate cancers, today announced that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results